539 related articles for article (PubMed ID: 25779971)
1. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.
Fonte C; Fatigoni S; Roila F
Crit Rev Oncol Hematol; 2015 Aug; 95(2):214-21. PubMed ID: 25779971
[TBL] [Abstract][Full Text] [Related]
2. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Sutherland A; Naessens K; Plugge E; Ware L; Head K; Burton MJ; Wee B
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012555. PubMed ID: 30246876
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.
Navari RM
Eur J Pharmacol; 2014 Jan; 722():180-6. PubMed ID: 24157985
[TBL] [Abstract][Full Text] [Related]
6. Optimal selection of antiemetics in children receiving cancer chemotherapy.
Roila F; Aapro M; Stewart A
Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
[TBL] [Abstract][Full Text] [Related]
8. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].
Benze G; Geyer A; Alt-Epping B; Nauck F
Schmerz; 2012 Sep; 26(5):481-99. PubMed ID: 22983450
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine for nausea and vomiting.
Licup N
Am J Hosp Palliat Care; 2010 Sep; 27(6):432-4. PubMed ID: 20508243
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.
Langley-DeGroot M; Ma JD; Hirst J; Roeland EJ
J Pain Palliat Care Pharmacother; 2015 Jun; 29(2):148-52. PubMed ID: 26095486
[TBL] [Abstract][Full Text] [Related]
12. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
[TBL] [Abstract][Full Text] [Related]
14. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.
Vig S; Seibert L; Green MR
J Cancer Res Clin Oncol; 2014 Jan; 140(1):77-82. PubMed ID: 24173694
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.
Chanthawong S; Subongkot S; Sookprasert A
J Med Assoc Thai; 2014 Mar; 97(3):349-55. PubMed ID: 25123016
[TBL] [Abstract][Full Text] [Related]
18. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Navari RM; Qin R; Ruddy KJ; Liu H; Powell SF; Bajaj M; Dietrich L; Biggs D; Lafky JM; Loprinzi CL
N Engl J Med; 2016 Jul; 375(2):134-42. PubMed ID: 27410922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]